Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - trecondi
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp133076b034a4711dfc1fe81f7acd828f
identifier: http://ema.europa.eu/identifier
/EU/1/18/1351/001 (1 g, 1 vial)
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Trecondi 1 g powder for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-133076b034a4711dfc1fe81f7acd828f
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/18/1351/001 (1 g, 1 vial)
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - trecondi
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Trecondi contains the active substance treosulfan, which belongs to a group of medicines called alkylating agents. Treosulfan is used to prepare patients for bone marrow transplant (haematopoietic stem cell transplantation). Treosulfan destroys the bone marrow cells and enables the transplant of new bone marrow cells which leads to the production of healthy blood cells.
Trecondi is used as a treatment before blood stem cell transplantation in adults and in adolescents and children older than one month with cancer and non-cancerous disorders.
Trecondi must not be given to you
if you are allergic to treosulfan,
if you suffer from an active uncontrolled infection,
if you suffer from severe heart, lung, liver or kidney diseases,
if you suffer from hereditary DNA repair disorder, a condition that reduces the ability to repair DNA (which carries your genetic information),
if you are pregnant, or think you may be pregnant.
Warnings and precautions
Trecondi is a cell-killing (cytotoxic) medicine that is used to decrease the number of blood cells. At the recommended dose, this is the desired effect. You will have regular blood tests during treatment to check your blood cell counts do not fall too low.
In order to prevent and treat infections, you will be given medicines, such as antibiotics, antifungals or antivirals.
Trecondi may increase the risk of having another cancer in the future.
Since inflammation of the oral mucosa is a common side effect of this medicine, you should pay attention to adequate oral hygiene. Preventive measures such as the use of mouthwashes (e.g. with barrier protectants, antimicrobials) or application of ice within the oral cavity (lessens blood flow to the oral mucosa and reduces the amount of treosulfan reaching the cell) is recommended.
You must not receive live vaccines during treatment with treosulfan.
Trecondi may cause symptoms of the menopause (absence of menstrual periods).
Children and adolescents Fits (seizures) may occur very rarely in infants of less than 4 months of age. Children younger than 1 year may have more severe side effects that affect breathing than older ones. Your child will be monitored for signs of side effects affecting nerves and breathing problems.
Nappy rash with sores of the area around the anus (perianal) may occur in infants, toddlers and children wearing nappies because treosulfan passed out in the urine can damage the skin. Therefore, nappies should be changed frequently during 6 8 hours after each dose of this medicine.
There is not sufficient information on the use of treosulfan in children aged less than 1 month.
Other medicines and Trecondi Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Pregnancy, breast-feeding and fertility You must not get pregnant during treatment with this medicine and up to 6 months after treatment. Use an effective method of contraception when either you or your partner is receiving this medicine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you receive this medicine.
You should stop breast-feeding before starting treatment with this medicine.
If you are a man treated with this medicine, you should not father a child during and up to 6 months after treatment.
This medicine may make you infertile and it may not be possible for you to get pregnant after treatment with it. If you are concerned about having children, you should discuss this with your doctor before treatment. Men should seek advice about the possibility of sperm preservation before starting therapy.
Driving and using machines This medicine can cause nausea, vomiting and dizziness which may reduce your ability to drive or use machines. If you are affected, do not drive or use machines.
Use in adults This medicine is used in combination with fludarabine. The recommended dose is 10 14 g/m body surface area (calculated using your height and weight).
Use in children and adolescents This medicine is used in combination with fludarabine and in most cases also with thiotepa. The recommended dose is 10 14 g/m body surface area.
How Trecondi is given This medicine will be given to you by your doctor. It is given by drip (infusion) into a vein over 2 hours for 3 days before blood stem cell infusion.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects The most serious side effects of treosulfan therapy or the transplant procedure include:
Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events.
Adults
A list of all other side effects is set out below according to how common they are.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (frequency cannot be estimated from the available data)
Children and adolescents
A list of all other side effects is set out below according to how common they are.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Not known (frequency cannot be estimated from the available data)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP . The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
For storage conditions after reconstitution of the medicine, see the information below for healthcare professionals.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Trecondi contains
The active substance is treosulfan. This medicine contains no other ingredients.
Trecondi 1 g powder for solution for infusion 1 vial of powder contains 1 g of treosulfan.
Trecondi 5 g powder for solution for infusion 1 vial of powder contains 5 g of treosulfan.
After reconstitution, 1 mL of the solution contains 50 mg treosulfan.
What Trecondi looks like and contents of the pack White crystalline powder in a glass vial with a rubber stopper and aluminium cap. Trecondi is available in packs containing 1 or 5 vials (type I glass).
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer medac Gesellschaft f r klinische Spezialpr parate mbH Theaterstr. 6 22880 Wedel Germany Tel.:
+49 4103 8006-0 Fax:
+49 4103 8006-Email: contact@medac.de
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-133076b034a4711dfc1fe81f7acd828f
Resource Composition:
Generated Narrative: Composition composition-en-133076b034a4711dfc1fe81f7acd828f
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/18/1351/001 (1 g, 1 vial)status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - trecondi
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp133076b034a4711dfc1fe81f7acd828f
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp133076b034a4711dfc1fe81f7acd828f
identifier:
http://ema.europa.eu/identifier
/EU/1/18/1351/001 (1 g, 1 vial)type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Trecondi 1 g powder for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en